Latest filing published 19 Jul 2022 for Keros Therapeutics, Inc., €14k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Jennifer Lachey, listed as senior executive, appears in our data through filings on Keros Therapeutics, Inc. shares, published by SEC (Form 4). In total, 17 filings cover trades dated from 11 May 2021 to 15 July 2022.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
On 19 July 2022 came the latest disclosure, an option exercise for €14k in Keros Therapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
17 of 17 declarations